| scholarly article | Q13442814 |
| P50 | author | Mohammed Altigani Abdalla | Q97521499 |
| P2093 | author name string | Thozhukat Sathyapalan | |
| Harshal Deshmukh | |||
| Stephen Atkin | |||
| P2860 | cites work | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| Lifestyle changes in women with polycystic ovary syndrome | Q24234000 | ||
| MicroRNA genes are transcribed by RNA polymerase II | Q24562649 | ||
| The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study | Q25257236 | ||
| Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives | Q26746239 | ||
| Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant | Q26747727 | ||
| Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes | Q26800961 | ||
| Dyslipidemia in women with polycystic ovary syndrome | Q27025695 | ||
| Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study | Q46607817 | ||
| A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. | Q46646075 | ||
| Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome | Q46706686 | ||
| The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery | Q46724489 | ||
| Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model | Q46791363 | ||
| Randomized trial of lifestyle modification and pharmacotherapy for obesity | Q46807914 | ||
| Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study | Q46856627 | ||
| The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome | Q47143029 | ||
| A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects | Q47196326 | ||
| Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial | Q47281414 | ||
| Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome | Q47287008 | ||
| Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without Type 2 diabetes | Q47383540 | ||
| The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes | Q47747717 | ||
| A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents | Q48246762 | ||
| DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY. | Q49964159 | ||
| Vitamin B12 deficiency and the knowledge and practice of physicians regarding screening for vitamin B12 deficiency among type 2 diabetic patients on metformin in selected hospitals in Riyadh, Saudi Arabia | Q92969166 | ||
| Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | Q92980564 | ||
| LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept | Q93349907 | ||
| Biogenesis of small RNAs in animals | Q27861013 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials | Q28073603 | ||
| Inositol Treatment and ART Outcomes in Women with PCOS | Q28077261 | ||
| The widespread regulation of microRNA biogenesis, function and decay | Q28131796 | ||
| A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes | Q28282265 | ||
| Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates | Q30368984 | ||
| Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis | Q30829257 | ||
| Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data | Q33195173 | ||
| Statins in the treatment of polycystic ovary syndrome | Q33789151 | ||
| Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity | Q33886379 | ||
| Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. | Q33908763 | ||
| Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS. | Q33952149 | ||
| The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes | Q34026140 | ||
| Urinary chiro- and myo-inositol levels as a biological marker for type 2 diabetes mellitus. | Q34033525 | ||
| The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study | Q34091483 | ||
| Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects | Q34136304 | ||
| Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOS. | Q34314979 | ||
| Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches | Q34364053 | ||
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 | ||
| A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) | Q34585609 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates | Q34975539 | ||
| Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis | Q34985373 | ||
| The psychiatric side-effects of rimonabant | Q34990771 | ||
| Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. | Q35007744 | ||
| The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls | Q35312833 | ||
| Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. | Q35695148 | ||
| Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis | Q42209597 | ||
| Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. | Q42474494 | ||
| Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study | Q42508741 | ||
| Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q42950914 | ||
| Mechanism of action of DPP-4 inhibitors--new insights | Q43235398 | ||
| Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). | Q43291794 | ||
| Myo-inositol may prevent gestational diabetes in PCOS women | Q43429253 | ||
| Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial | Q43688567 | ||
| Metformin in women with PCOS, pros | Q43852376 | ||
| Effects of orlistat on fat-soluble vitamins in obese adolescents | Q44069742 | ||
| Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial | Q44251536 | ||
| Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome | Q44473192 | ||
| Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin | Q44653784 | ||
| Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome | Q45006023 | ||
| Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. | Q45145839 | ||
| Association of polycystic ovary syndrome with cardiovascular risk factors. | Q45917076 | ||
| Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. | Q45986103 | ||
| Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). | Q46172452 | ||
| The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. | Q46305285 | ||
| Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome | Q46473099 | ||
| Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses | Q46484240 | ||
| Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. | Q46545539 | ||
| Incretin levels in polycystic ovary syndrome. | Q46568299 | ||
| A two-year randomized trial of obesity treatment in primary care practice | Q35766121 | ||
| SGLT-2 Inhibitors: A New Mechanism for Glycemic Control | Q35906490 | ||
| Recent advances in the treatment of polycystic ovary syndrome | Q35906966 | ||
| Defining the role of bariatric surgery in polycystic ovarian syndrome patients | Q35906974 | ||
| Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome | Q35995837 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Medical management of metabolic dysfunction in PCOS. | Q36132055 | ||
| Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis | Q36298211 | ||
| Evidence for statin therapy in polycystic ovary syndrome | Q36327934 | ||
| D-chiro-inositol metabolism in diabetes mellitus | Q36626417 | ||
| Quality of life and psychological well being in polycystic ovary syndrome | Q36835266 | ||
| Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. | Q37023259 | ||
| Role of diet in the treatment of polycystic ovary syndrome. | Q37119729 | ||
| Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). | Q37235840 | ||
| HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? | Q37253000 | ||
| Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes | Q37331171 | ||
| Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. | Q37343173 | ||
| Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). | Q37595940 | ||
| Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment | Q37631759 | ||
| The physiologic role of incretin hormones: clinical applications. | Q37728788 | ||
| The Effect of Low Carbohydrate Diets on Fertility Hormones and Outcomes in Overweight and Obese Women: A Systematic Review. | Q37729636 | ||
| Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial | Q37736727 | ||
| Exercise therapy in polycystic ovary syndrome: a systematic review | Q37787632 | ||
| Polycystic ovary syndrome: etiology, pathogenesis and diagnosis | Q37832125 | ||
| Dyslipidemia in PCOS. | Q37971240 | ||
| Insulin resistance: a significant risk factor of endometrial cancer | Q37997180 | ||
| Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence | Q38305698 | ||
| Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis. | Q38645244 | ||
| A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries | Q38667575 | ||
| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
| The New Biology and Pharmacology of Glucagon. | Q38919742 | ||
| Bariatric surgery for obesity and metabolic disorders: state of the art. | Q39023968 | ||
| Risk of atherosclerosis in women with polycystic ovary syndrome: a study from South India | Q40109816 | ||
| Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction | Q40166604 | ||
| PPAR-gamma: adipogenic regulator and thiazolidinedione receptor | Q41755813 | ||
| Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial | Q42166214 | ||
| Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. | Q50610497 | ||
| Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome. | Q51244187 | ||
| Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. | Q51357963 | ||
| A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. | Q51373947 | ||
| Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin. | Q51480546 | ||
| Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome | Q51607514 | ||
| Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. | Q51748822 | ||
| The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. | Q51832665 | ||
| Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome | Q58836759 | ||
| Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome | Q58836764 | ||
| Metabolic effects of glucagon in humans | Q60944099 | ||
| Dietary Composition in the Treatment of Polycystic Ovary Syndrome: A Systematic Review to Inform Evidence-Based Guidelines | Q61958552 | ||
| Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | Q63170509 | ||
| The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome | Q64084410 | ||
| Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity | Q64232819 | ||
| Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis | Q64237430 | ||
| Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. | Q64951371 | ||
| Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases | Q67294340 | ||
| Sibutramine reduces food intake in non-dieting women with obesity | Q74397262 | ||
| Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology | Q77690927 | ||
| The metabolic syndrome in polycystic ovary syndrome | Q79783210 | ||
| Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass | Q80151319 | ||
| Metformin versus lifestyle changes in treating women with polycystic ovary syndrome | Q83395696 | ||
| The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study | Q84357802 | ||
| Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study | Q85043105 | ||
| Pharmacologic and Pharmacodynamic Equivalence of 2 Formulations of Orlistat | Q88369357 | ||
| Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome | Q88662229 | ||
| Effects of a ketogenic diet in overweight women with polycystic ovary syndrome | Q89905987 | ||
| Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: a cross-sectional study | Q90097847 | ||
| Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome | Q90140092 | ||
| Effects of dipeptidyl peptidase-4 inhibitors on transforming growth factor-β1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats | Q90266880 | ||
| Evaluation of vitamin B12 monitoring in patients on metformin in urban ambulatory care settings | Q90582305 | ||
| Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis | Q90672550 | ||
| The clinical potential of circulating microRNAs in obesity | Q90703773 | ||
| The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls | Q90840367 | ||
| Discovering metformin-induced vitamin B12 deficiency in patients with type 2 diabetes in primary care | Q90939918 | ||
| Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial | Q91069220 | ||
| Expression of microRNA in follicular fluid in women with and without PCOS | Q91198889 | ||
| The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance | Q91229039 | ||
| Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review | Q91440606 | ||
| Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials | Q91495531 | ||
| The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome | Q91782126 | ||
| Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort | Q91916654 | ||
| Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome | Q92038416 | ||
| Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study | Q92331782 | ||
| Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls | Q92437260 | ||
| Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity | Q92698672 | ||
| GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis | Q92958714 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | polycystic ovary syndrome | Q500816 |
| polycystic ovary | Q5547896 | ||
| P304 | page(s) | 2042018820938305 | |
| P577 | publication date | 2020-07-06 | |
| P1433 | published in | Therapeutic advances in endocrinology and metabolism | Q26853790 |
| P1476 | title | A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome | |
| P478 | volume | 11 |
Search more.